Implantable insulin pumps. A position statement about their clinical use

Diabetes and Metabolism

Volumn 33, Issue 2, 2007, Pages 158-166

  Renard, E ^a   Schaepelynck Belicar P ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Implantable devices; Intensive insulin therapy; Intraperitoneal insulin delivery; Review; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; INSULIN ANTIBODY; NEUTRAL INSULIN;

ANTIBODY PRODUCTION; ARTICLE; CATHETER OCCLUSION; CONTINUOUS INFUSION; DIABETIC PATIENT; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PATIENT SAFETY; QUALITY OF LIFE; RECURRENT DISEASE; REGISTER; SYSTEMATIC REVIEW;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; HUMANS; INSULIN INFUSION SYSTEMS; MULTICENTER STUDIES; SAFETY;

EID: 34147147578     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2006.10.004     Document Type: Article

References (62)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
2. The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 19 (1996) 195-203
3. The Writing Team for the Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002) 2563-2569
4. Muller U.A., Femerling M., Reinauer K.M., Risse A., Voss M., Jorgens V., et al. Intensified treatment and education of type 1 diabetes as clinical routine. A nationwide quality-circle experience in Germany (ASD). Diabetes Care 22 Suppl 2 (1999) B29-B34
5. Hunger-Dathe W., Braun A., Muller U.A., Schiel R., Femerling M., and Risse A. Insulin pump therapy in patients with type 1 diabetes mellitus: results of the Nationwide Quality Circle in Germany (ASD) 1999-2000. Exp. Clin. Endocrinol. Diabetes 111 (2003) 428-434
6. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with Type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. Diabet. Med. 20 Suppl 3 (2003) 4-5
7. Lalli C., Ciofetta M., Del Sindaco P., Tolone E., Pampanelli S., Compagnucci P., et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22 (1999) 468-477
8. Melki V., Renard E., Lassmann-Vague V., Boivin S., Guerci B., Hanaire-Broutin H., et al. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21 (1998) 977-982
9. Vague P., Selam J.L., Skeie S., De Leeuw I., Elte J.W., Haahr H., et al. Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycaemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
10. Porcellati F., Rossetti P., Pampanelli S., Fanelli C.G., Torlone E., Scionti L., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet. Med. 21 (2004) 1213-1220
11. Wredling R., Liu D., Lins P.E., and Adamson U. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion. Diabete Metab. 17 (1991) 456-459
12. Selam J.L., Micossi P., Dunn F.L., and Nathan D.M. Clinical trial of programmable implantable insulin pumps for type 1 diabetes. Diabetes Care 15 (1992) 877-885
13. Selam J.L., and Charles M.A. Devices for insulin administration. Diabetes Care 13 (1990) 955-979
14. Saudek C.D., Selam J.L., Pitt H.A., Waxman K., Rubio M., Jeandidier N., et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N. Engl. J. Med. 321 (1989) 574-579
15. Broussolle C., Jeandidier N., Hanaire-Broutin H., and for the Evadiac Study Group. French multicenter experience with implantable insulin pumps. Lancet 343 (1994) 514-515
16. Grau U., and Saudek C.D. Stable insulin preparation for implanted insulin pumps. Laboratory and animal trials. Diabetes 36 (1987) 1453-1459
17. Lassmann-Vague V., Guerci B., Hanaire-Broutin H., Pinget M., Renard E., Selam J.L., et al., on behalf of the EVADIAC group. Use of implantable insulin pumps: the EVADIAC position. Diabete Metab. 23 (1997) 242-250
18. Gin H., Melki V., Guerci B., Catargi B., and the EVADIAC Study Group. Clinical evaluation of a newly designed compliant side port catheter for an insulin implantable pump: the EVADIAC experience. Diabetes Care 24 (2001) 175
19. Gin H., Renard E., Melki V., Boivin S., Schaepelynck-Belicar P., Guerci B., et al., the EVADIAC Study Group. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 29 (2003) 602-607
20. Renard E., Bringer J., Jacques-Apostol D., Lauton D., Mestre C., Costalat G., et al. Complications of the pump-pocket may represent a significant cause of incidents with implanted systems for intraperitoneal insulin delivery. Diabetes Care 17 (1994) 1064-1066
21. Scavini M., Cristallo M., Sarmiento M., Dunn F.L., and The infusaid multicenter Implantable insulin pump study group. Pump-pocket complications during long-term insulin delivery using an implanted programmable pump. Diabetes Care 19 (1996) 384-385
22. Belicar P., Lassmann-Vague V., and the EVADIAC Study Group. Local adverse events associated with long-term treatment by implantable insulin pumps. Diabetes Care 21 (1998) 325-326
23. Renard E., Rostane T., Carriere C., Marchandin H., Jacques-Apostol D., Lauton D., et al. Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. Diabetes Metab. 27 (2001) 62-65
24. Hanaire-Broutin H., Broussolle C., Jeandidier N., Renard E., Guerci B., Haardt M.J., et al., the EVADIAC Study Group. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: a multicenter study. Diabetes Care 18 (1995) 388-392
25. Renard E., Bouteleau S., Jacques-Apostol D., Lauton D., Gibert-Boulet F., Costalat G., et al. Insulin underdelivery from implanted pumps using peritoneal route: determinant role of insulin-pump compatibility. Diabetes Care 19 (1996) 812-817
26. Renard E., Souche C., Jacques-Apostol D., Lauton D., Gibert-Boulet F., Costalat G., et al. Improved stability of insulin delivery from implanted pumps using a new preparation process for infused insulin. Diabetes Care 22 (1999) 1371-1372
27. Boivin S., Belicar P., Melki V., and EVADIAC Group. Assessment of in vivo stability of a new insulin preparation for implantable insulin pumps. Diabetes Care 22 (1999) 2089-2090
28. Renard E., Baldet P., Picot M.C., Jacques-Apostol D., Lauton D., Costalat G., et al. Catheter complications with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors and obstructing materials. Diabetes Care 18 (1995) 300-306
29. Melki V., Tall P., and Hanaire-Broutin H. Intérêt du scanner dans l'exploration des problèmes de cathéter au cours du traitement du diabète par pompe à insuline implantable. Infusystèmes 21 (2004) 17-21
30. Olsen C.L., Chan E., Turner D.S., Iravani M., Nagy M., Selam J.L., et al. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care 17 (1994) 169-176
31. Jeandidier N., Boivin S., Sapin R., Rosart-Ortega F., Uring-Lambert B., Reville P., et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38 (1995) 577-584
32. Lassmann-Vague V., Belicar P., Raccah D., Vialettes B., Sodoyez J.C., and Vague P. Immunogenicity of long-term intraperitoneal insulin administration with programmable pumps: metabolic consequences. Diabetes Care 18 (1995) 498-503
33. Jeandidier N., Boullu S., Busch-Brafin M.S., Chabrier G., Sapin R., Gasser F., et al. Comparison of antigenicity of Hoechst 21 PH insulin infusion using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. Diabetes Care 25 (2002) 84-88
34. Kessler L., Tritschler S., Bohbot A., Sigrist S., Karsten V., Boivin, et al. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. Diabetes Care 24 (2001) 302-307
35. Lassmann-Vague V., Belicar P., Alessis C., Raccah D., Vialettes B., and Vague P. Insulin kinetics in type 1 diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies. Diabet. Med. 13 (1996) 1051-1055
36. Hanaire-Broutin H., Melki V., and Tauber J.P. Treatment of acquired immune insulin resistance with i.v. immunoglobulins. Diabetologia 42 (1999) 1378
37. Melki V., Dufaitre-Patouraux L., Hanaire-Broutin H., and pour le groupe EVADIAC. Prévalence et incidence des maladies auto-immunes chez des diabétiques de type 1 traités par pompe externe ou implantables. Diabetes Metab 29 (2003) 1S50 [Abstract]
38. Renard E., Raingeard I., Costalat G., Apostol D., Lauton D., Boulet F., et al. Aseptic peritonitis revealed through recurrent catheter obstructions in type 1 diabetic patients treated with continuous peritoneal insulin infusion. Diabetes Care 27 (2004) 276-277
39. Schade D.S., Eaton R.P., Friedman N.M., and Spencer W.J. Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia 19 (1980) 35-39
40. Schade D.S., Eaton R.P., Davis T., Akiya F., Phinney E., Kubica R., Vaughn E.A., et al. The kinetics of peritoneal insulin absorption. Metabolism 30 (1981) 149-155
41. Selam J.L., Raymond L., Jacquemin J.L., Orsetti A., Richard J.L., and Mirouze J. Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. Diabetes Metab. 11 (1985) 170-173
42. Schaepelynck Belicar P., Vague P., and Lassmann-Vague V. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps. Diabetes Metab. 29 4 Pt 1 (2003) 344-348
43. Nelson J.A., Stephen R., Landau S.T., Wilson D.E., and Tyler F.H. Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized, unrestrained swine. Metabolism 31 (1982) 969-972
44. Nathan D.M., Dunn F.L., Bruch J., McKitrick C., Larkin M., Haggan C., et al. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycaemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am. J. Med. 100 (1996) 412-417
45. Oskarsson P.R., Lins P.E., Backman L., and Adamson U.C. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. Diabetes Metab. 26 (2000) 118-124
46. Oskarsson P.R., Lins P.E., Wallberg-Henriksson H., and Adamson U.C. Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion. Diabetes Metab. 25 (1999) 491-497
47. Point study group. One-year trial of a remote-controlled implantable infusion system in type 1 diabetic patients. Lancet i (1988) 866-869
48. Jeandidier N., Selam J.L., Renard E., Guerci B., Lassman-Vague V., Rocher L., et al., for the Evadiac study group. Decreased severe hypoglycaemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Diabetes Care 19 (1996) 780
49. Catargi B., Meyer L., Melki V., Renard E., Jeandidier N., and for the EVADIAC study group. Comparison of blood glucose stability and HbA1c between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes Metab. 28 (2002) 133-137
50. De Vries J.H., Eskes S.A., Snoek F.J., Pouwer F., Van Ballegooie E., Spijker A.J., et al. Continuous intraperitoneal insulin infusion in patients with 'brittle' diabetes: favourable effects on glycaemic control and hospital stay. Diabet. Med. 19 (2002) 496-501
51. Selam J.L., Raccah D., Jeandidier N., Lozano J.L., Waxman K., and Charles M.A. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 15 (1992) 53-58
52. Haardt M.J., Selam J.L., Slama G., Bethoux J.P., Dorange C., Mace B., et al. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes. Diabetes Care 17 (1994) 847-851
53. Saudek C.D., Duckworth W.C., Giobbie-Hurder A., Henderson W.G., Henry R.R., Kelley D.E., et al. Implantable insulin pumps vs. multiple dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. JAMA 276 (1996) 1322-1327
54. Renard E., Apostol D., Lauton D., Boulet F., and Bringer J. Quality of life in diabetic patients treated by insulin pumps. QoL Newsletter 28 (2002) 11-13
55. Baillot-Rudoni S., Apostol D., Vaillant G., Brun J.M., Renard E., and on behalf of the EVADIAC Study Group. Implantable pump therapy restores metabolic control and quality of life in type 1 diabetic patients with Buschke's non systemic scleroderma. Diabetes Care 29 (2006) 1710
56. Paulsen E.P., Courtney J.W., and Duckworth W.C. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 28 (1979) 640-645
57. Riveline J.P., Vantyghem M.C., Fermon C., Brunet C., Gautier J.F., Renard E., et al. Subcutaneous insulin resistance successfully circumvented on long term by peritoneal insulin delivery from an implantable pump in four diabetic patients. Diabetes Metab. 31 (2005) 496-498
58. Renard E., Lauton D., Bonifacj C., Costalat G., Jacques D., Bringer J., et al. Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin-dependent) diabetes mellitus previously treated by external pumps. Diabetes Metab. 19 (1993) 364-371
59. ®: results from the DiaPort-001 study. Diabetologia 46 Suppl 2 (2003) 127 [Abstract]
60. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000) 230-238
61. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., et al. Five-year follow-up after clinical islet transplantation. Diabetes 54 (2005) 2060-2069
62. Belicar P., Jeandidier N., Renard E., Boivin S., Gross P., Pinget M., et al. Implanted insulin pump may represent a chance for young women with unstable type 1 diabetes to give birth. Diabetes Care 22 (1999) 1001-1002